STARTRK-2 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT-Nummer:
NCT02568267
Studienbeginn:
November 2015
Letztes Update:
20.01.2021
Wirkstoff:
Entrectinib
Indikation (Clinical Trials):
Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Thyroid Cancer, Papillary
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
Phase 2
Sponsor:
Hoffmann-La Roche
Collaborator:
-
Studienleiter
Study Director
Hoffmann-La Roche
Kontakt
Kontakt:
Phone: 888-662-6728 (U.S. and Canada)
E-Mail: global-roche-genentech-trials@gene.com» Kontaktdaten anzeigen
Studienlocations (3 von 150)
10117 Berlin
(Berlin)
GermanyZurückgezogen» Google-MapsEvang. Lungenklinik Berlin Klinik für Pneumologie
13125 Berlin
(Berlin)
GermanyRekrutierend» Google-MapsUniversitaetsklinikum Carl Gustav Carus TU Dresden
01307 Dresden
(Sachsen)
GermanyRekrutierend» Google-Maps
82131 Gauting
(Bayern)
GermanyZurückgezogen» Google-MapsUniversitaetsmedizin Goettingen; Abteilung Haematologie und Onkologie
37075 Göttingen
(Niedersachsen)
GermanyRekrutierend» Google-MapsNCT Uniklinikum Heidelberg; Medizinische Onkologie
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-MapsUniversitaetsklinikum Koeln; Innere Medizin I, Haematologie
50937 Köln
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-MapsWestern Regional Medical Center at Cancer Treatment Centers of America
85338 Goodyear
United StatesZurückgezogen» Google-MapsDignity Health St Joseph's Hospital and Medical Center
85013 Phoenix
United StatesRekrutierend» Google-MapsMayo Clinic
85259 Scottsdale
United StatesAktiv, nicht rekrutierend» Google-MapsCity of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics
91010 Duarte
United StatesRekrutierend» Google-MapsScripps Clinic
92037 La Jolla
United StatesAktiv, nicht rekrutierend» Google-MapsUniversity of California San Diego Moores Cancer Center; Dept of Lung Cancer
92093 La Jolla
United StatesRekrutierend» Google-MapsUniversity of Southern California Medical Center
90033 Los Angeles
United StatesRekrutierend» Google-MapsUniv Of California Irvine College Of Medicine; 300194620
92868 Orange
United StatesAktiv, nicht rekrutierend» Google-MapsSouthern California Kaiser Permanente
92108 San Diego
United StatesRekrutierend» Google-MapsUCSF Mount Zion Medical Ctr
94115 San Francisco
United StatesAktiv, nicht rekrutierend» Google-MapsSarcoma Oncology Center
90403 Santa Monica
United StatesRekrutierend» Google-MapsUniversity of Colorado Cancer Center
80045 Aurora
United StatesRekrutierend» Google-MapsYale University
06510 New Haven
United StatesAktiv, nicht rekrutierend» Google-MapsGeorgetown University Medical Center Lombardi Cancer Center
20007 Washington
United StatesAktiv, nicht rekrutierend» Google-MapsFlorida Cancer Specialists - Sarasota
34232 Sarasota
United StatesAktiv, nicht rekrutierend» Google-MapsH. Lee Moffitt Cancer Center and Research Inst.
33612 Tampa
United StatesRekrutierend» Google-MapsCleveland Clinic Florida
33331 Weston
United StatesZurückgezogen» Google-MapsUniversity Cancer & Blood Center, LLC; Research
30607 Athens
United StatesAktiv, nicht rekrutierend» Google-MapsWinship Cancer Institute
30322 Atlanta
United StatesAktiv, nicht rekrutierend» Google-MapsSoutheastern Regional Medical Center, Inc.
30265 Newnan
United StatesAbgeschlossen» Google-MapsUniversity of Hawaii Cancer Center
96813 Honolulu
United StatesZurückgezogen» Google-MapsNorthwestern University
60611 Chicago
United StatesAktiv, nicht rekrutierend» Google-MapsAdvocate Medical Group - Park Ridge, Luther Lane - Oncology
60068 Park Ridge
United StatesAbgeschlossen» Google-MapsMidwestern Regional Medical Center
60099 Zion
United StatesRekrutierend» Google-MapsWeinberg Cancer Institution at Franklin Square
21237 Baltimore
United StatesRekrutierend» Google-MapsMassachusetts General Hospital
02114 Boston
United StatesRekrutierend» Google-MapsBeth Israel Deaconess Medical Center
02215 Boston
United StatesAktiv, nicht rekrutierend» Google-MapsDana Farber Cancer Institute
02215 Boston
United StatesRekrutierend» Google-MapsUniversity of Michigan Comprehensive Cancer Center
48109 Ann Arbor
United StatesAktiv, nicht rekrutierend» Google-MapsKarmanos Cancer Center
48201 Detroit
United StatesAktiv, nicht rekrutierend» Google-MapsHenry Ford Hospital
48202 Detroit
United StatesAktiv, nicht rekrutierend» Google-MapsRegents of the University of Minnesota
55455 Minneapolis
United StatesRekrutierend» Google-MapsWashington University
63128 Saint Louis
United StatesAktiv, nicht rekrutierend» Google-MapsComprehensive Cancer Centers of Nevada (CCCN) - Central Valley
89169 Las Vegas
United StatesRekrutierend» Google-MapsDartmouth Hitchcock Medical Center
03756 Lebanon
United StatesZurückgezogen» Google-MapsNorth Shore Hem Onc Associates
11733 East Setauket
United StatesAktiv, nicht rekrutierend» Google-MapsMemorial Sloan Kettering Cancer Center
10065 New York
United StatesRekrutierend» Google-MapsLevine Cancer Institute
28204 Charlotte
United StatesRekrutierend» Google-MapsDuke Cancer Institute
27710 Durham
United StatesAktiv, nicht rekrutierend» Google-MapsCleveland Clinic
44195 Cleveland
United StatesZurückgezogen» Google-MapsOSU, James Cancer Hospital
43210 Columbus
United StatesRekrutierend» Google-MapsCancer Treatment Centers of America; Tulsa
74133 Tulsa
United StatesAktiv, nicht rekrutierend» Google-MapsProvidence Portland Medical Center
97213 Portland
United StatesZurückgezogen» Google-MapsOregon Health & Science Univ
97239 Portland
United StatesAktiv, nicht rekrutierend» Google-MapsCancer Treatment Centers of America - Eastern Regional Medical Center
19124 Philadelphia
United StatesAbgeschlossen» Google-MapsMary Crowley Medical Research Center
75230 Dallas
United StatesRekrutierend» Google-MapsUniversity Hospital Medical Oncology Clinic; Harold C. Simmons Comprehensive Cancer Center
75390 Dallas
United StatesZurückgezogen» Google-MapsUniversity of Texas MD Anderson Cancer Center
77030 Houston
United StatesRekrutierend» Google-MapsBaylor Scott & White Health
76502 Temple
United StatesRekrutierend» Google-MapsUniversity of Utah Hospitals & Clinics
84132 Salt Lake City
United StatesRekrutierend» Google-MapsVirginia Cancer Specialists, PC
22031 Fairfax
United StatesRekrutierend» Google-MapsVirginia Oncology Associates - Hampton
23666 Hampton
United StatesRekrutierend» Google-MapsUniversity of Washington Seattle Cancer Care Alliance
98195 Seattle
United StatesRekrutierend» Google-MapsWheaton Franciscan Cancer Care-All Saints
53132 Franklin
United StatesZurückgezogen» Google-MapsBorder Medical Oncology Research Unit
2640 Albury
AustraliaZurückgezogen» Google-MapsLiverpool Hospital
2170 Liverpool
AustraliaRekrutierend» Google-MapsNewcastle Private Hospital
2305 New Lambton Heights
AustraliaAktiv, nicht rekrutierend» Google-MapsFlinders Medical Centre
5042 Bedford Park
AustraliaRekrutierend» Google-MapsAustin Hospital
3084 Heidelberg
AustraliaRekrutierend» Google-MapsAntwerp University Hospital
2650 Edegem
BelgiumRekrutierend» Google-MapsBeijing Cancer Hospital
100142 Beijing
ChinaNoch nicht rekrutierend» Google-MapsBeijing Union Hospital
100730 Beijing
ChinaNoch nicht rekrutierend» Google-MapsHunan Cancer Hospital
410013 Changsha City
ChinaNoch nicht rekrutierend» Google-MapsSichuan Provincial Cancer Hospital
610041 Chengdu
ChinaRekrutierend» Google-MapsFujian Provincial Cancer Hospital
350014 Fuzhou City
ChinaNoch nicht rekrutierend» Google-MapsCancer Center of Guangzhou Medical University
510000 Guangzhou
ChinaNoch nicht rekrutierend» Google-MapsHarbin Medical University Cancer Hospital
150081 Harbin
ChinaRekrutierend» Google-MapsShanghai chest hospital
200030 Shanghai
ChinaRekrutierend» Google-MapsFudan University Shanghai Cancer Center
200120 Shanghai
ChinaRekrutierend» Google-MapsShenzhen People's Hospital
510852 Shenzhen
ChinaNoch nicht rekrutierend» Google-MapsTianjin Cancer Hospital
300060 Tianjin
ChinaNoch nicht rekrutierend» Google-MapsUnion Hospital Tongji Medical College Huazhong University of Science and Technology
430023 Wuhan City
ChinaRekrutierend» Google-MapsZhejiang Cancer Hospital
310022 Zhejiang
ChinaRekrutierend» Google-MapsInstitut de Cancerologie de l Ouest
49055 Angers
FranceRekrutierend» Google-MapsInstitut Bergonie; Oncologie
33076 Bordeaux
FranceRekrutierend» Google-MapsCentre Oscar Lambret; Chir Cancerologie General
59000 Lille
FranceZurückgezogen» Google-MapsCentre Leon Berard; Departement Oncologie Medicale
69373 Lyon
FranceRekrutierend» Google-MapsHôpital de la Timone; Oncologie Médicale Hématologie & Soins Palliatifs
13385 Marseille cedex 5
FranceRekrutierend» Google-MapsHôpital Nord - AP-HM Marseille#; Service d'Oncologie Multidisciplinaire
13015 Marseille
FranceRekrutierend» Google-MapsInstitut de Recherche en Cancérologie de Montpellier
34298 Montpellier cedex 5
FranceRekrutierend» Google-MapsHôpital Européen Georges Pompidou; Hématologie Oncologie
75908 Paris cedex 15
FranceZurückgezogen» Google-MapsInstitut Curie; Oncologie Medicale
75231 Paris
FranceRekrutierend» Google-MapsInstitut De Cancerologie De L'ouest - Rene Gauducheau - Biology
44805 Saint Herblain
FranceRekrutierend» Google-MapsInstitut Claudius Regaud; Departement Oncologie Medicale
31059 Toulouse
FranceRekrutierend» Google-MapsInstitut Gustave Roussy; Pathologie Thoracique
94805 Villejuif cedex
FranceRekrutierend» Google-MapsHong Kong Integrated Oncology Centre
Hong Kong
Hong KongZurückgezogen» Google-MapsPrincess Margaret Hospital
Hong Kong
Hong KongRekrutierend» Google-MapsThe University of Hong Kong
Hong Kong
Hong KongRekrutierend» Google-MapsQueen Elizabeth Hospital
Kowloon
Hong KongRekrutierend» Google-MapsThe Chinese University of Hong Kong
123456 Shatin
Hong KongRekrutierend» Google-MapsSeconda Università degli Studi di Napoli; Servizio Epato-Gastroenterologia
80131 Napoli
ItalyRekrutierend» Google-MapsUniversità Campus Bio-Medico di Roma; Oncologia Medica
128 Roma
ItalyRekrutierend» Google-MapsAzienda Ospedaliero Universitaria San Martino; Lung Cancer Unit
16132 Genova
ItalyZurückgezogen» Google-MapsFondazione IRCCS Istituto Nazionale dei Tumori
20133 Milano
ItalyRekrutierend» Google-MapsAzienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck
20162 Milano
ItalyRekrutierend» Google-MapsFondazione del Piemonte per l'Oncologia - IRCCS;Ematologia
10060 Candiolo
ItalyAktiv, nicht rekrutierend» Google-MapsAzienda Ospedaliero-Universitaria S.Luigi Gonzaga; SSD Oncologia Polmonare
10043 Orbassano
ItalyZurückgezogen» Google-MapsA.O Città della Salute e della Scienza di Torino; Colorectal Cancer Unit (CRCU) - SSCVD
10126 Torino
ItalyZurückgezogen» Google-MapsAzienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico
56126 Pisa
ItalyRekrutierend» Google-MapsAzienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia ; S.C. Oncologia Medica
6132 Perugia
ItalyRekrutierend» Google-MapsIOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
35128 Padova
ItalyRekrutierend» Google-MapsAichi Cancer Center Hospital; Respiratory Medicine
464-8681 Aichi
JapanRekrutierend» Google-MapsNHO Shikoku Cancer Center; Dept of Respiratory Medicine
791-0280 Ehime
JapanRekrutierend» Google-MapsNHO Kyushu Cancer Center
811-1395 Fukuoka
JapanRekrutierend» Google-MapsHyogo Cancer Center, Dept of Respiratory Medicine
673-8558 Hyogo
JapanRekrutierend» Google-MapsNational Cancer Center Hospital; Dept of Respiratory Medicine
277-8577 Kashiwa-shi
JapanRekrutierend» Google-MapsMiyagi Cancer Center; Respiratory Medicine
981-1293 Miyagi
JapanRekrutierend» Google-MapsNiigata Cancer Center Hospital; Internal Medicine
951-8566 Niigata
JapanRekrutierend» Google-MapsOSAKA CITY GENERAL HOSPITAL;Medical Oncology
534-0021 Osaka
JapanRekrutierend» Google-MapsKindai University Hospital; Medical Oncology
589-8511 Osaka
JapanRekrutierend» Google-MapsShizuoka Cancer Center; Respiratory Internal Medicine
411-8777 Shizuoka
JapanRekrutierend» Google-MapsChungbuk National University Hospital
28644 Cheongju-si
Korea, Republic ofZurückgezogen» Google-MapsSamsung Medical Center
(0)6351 Seoul
Korea, Republic ofRekrutierend» Google-MapsSeoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-MapsSeverance Hospital, Yonsei University Health System
03722 Seoul
Korea, Republic ofRekrutierend» Google-MapsAsan Medical Center.
138-736 Seoul
Korea, Republic ofRekrutierend» Google-MapsNKI The Netherlands Cancer Institute
1066 CX Amsterdam
NetherlandsRekrutierend» Google-MapsLeids Universitair Medisch Centrum
2333 ZA Leiden
NetherlandsRekrutierend» Google-MapsUniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
80-214 Gdańsk
PolandRekrutierend» Google-MapsCentrum Onkologii-Instytut im.M.Sklodowskiej Curie; Dept of Nuclear Med. and Endocrine Oncology
44-101 Gliwice
PolandRekrutierend» Google-MapsMazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology
05-400 Otwock
PolandZurückgezogen» Google-MapsSzpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego; Chemotherapy
60-569 Poznań
PolandRekrutierend» Google-MapsCentrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego
02-781 Warszawa
PolandRekrutierend» Google-MapsNational University Hospital; Haematology/Oncology
119074 Singapore
SingaporeRekrutierend» Google-MapsNational Cancer Centre
169610 Singapore
SingaporeRekrutierend» Google-MapsCentro Nacional de Investigaciones Oncológicas(CNIO); Gastrointestinal Cancer Clinical Research Unit
28942 Fuenlabrada
SpainZurückgezogen» Google-MapsHospital Universitari Vall dHebron; Oncology
08035 Barcelona
SpainRekrutierend» Google-MapsHospital Universitario de La Princesa; Servicio de Oncologia
28006 Madrid
SpainZurückgezogen» Google-MapsHospital Universitario Ramon y Cajal; Servicio de Farmacia
28034 Madrid
SpainRekrutierend» Google-MapsHospital Universitario Clínico San Carlos; Servicio de Oncologia
28040 Madrid
SpainRekrutierend» Google-MapsHospital Universitario 12 de Octubre; Servicio de Oncologia
28041 Madrid
SpainRekrutierend» Google-MapsHospital Universitario La Paz; Servicio de Oncologia
28046 Madrid
SpainRekrutierend» Google-MapsSTART Madrid. Centro Integral Oncologico Clara Campal; Unidad de Fase I-Oncologica
28050 Madrid
SpainRekrutierend» Google-MapsHospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
29010 Malaga
SpainRekrutierend» Google-MapsHospital Universitario Virgen del Rocio; Servicio de Oncologia
41013 Sevilla
SpainRekrutierend» Google-MapsChanghua Christian Hospital
500 Chang Hua
TaiwanZurückgezogen» Google-MapsTaichung Veterans General Hospital
407 Taichung
TaiwanZurückgezogen» Google-MapsNational Cheng Kung University Hospital
70457 Tainan
TaiwanRekrutierend» Google-MapsTaipei Veterans General Hospital
11217 Taipei City
TaiwanRekrutierend» Google-MapsNational Taiwan University Hospital
10002 Taipei
TaiwanRekrutierend» Google-MapsCambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
CB2 0QQ Cambridge
United KingdomRekrutierend» Google-MapsSarah Cannon Research Institute
W1G 6AD London
United KingdomRekrutierend» Google-MapsChristie Hospital Nhs Trust; Medical Oncology
M2O 4BX Manchester
United KingdomRekrutierend» Google-Maps
Studien-Informationen
Brief Summary:This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for
the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene
fusion. Patients will be assigned to different baskets according to tumor type and gene
fusion.
Ein-/Ausschlusskriterien
Inclusion Criteria:- Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic
solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement
- Note: Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene
rearrangement of interest may be eligible provided they meet all other
inclusion/exclusion criteria
- For patients enrolled via local molecular testing, an archival or fresh tumor tissue
(unless medically contraindicated) is required to be submitted for independent central
molecular testing at Ignyta's CLIA laboratory post-enrollment
- Measurable or evaluable disease
- Patients with CNS involvement, including leptomeningeal carcinomatosis, which is
either asymptomatic or previously-treated and controlled, are allowed
- Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1,
or ALK inhibitors in patients who have tumors that harbor those respective gene
rearrangements)
- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged
NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are
prohibited.
- At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior
chemotherapy or small molecule targeted therapy
- At least 4 weeks must have elapsed since completion of antibody-directed therapy
- Prior radiotherapy is allowed if more than 14 days have elapsed since the end of
treatment
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life
expectancy of 4 weeks
- Adequate organ function as defined per protocol
- Ability to swallow entrectinib intact
- Other protocol specified criteria
Exclusion Criteria:
- Current participation in another therapeutic clinical trial
- Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in
patients who have tumors that harbor those respective gene rearrangements
- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged
NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are
prohibited.
- History of other previous cancer that would interfere with the determination of safety
or efficacy
- Familial or personal history of congenital bone disorders, bone metabolism alterations
or osteopenia
- Incomplete recovery from any surgery
- History of recent (within the past 3 months) symptomatic congestive heart failure or
ejection fraction ≤50% observed during screening for the study
- History of non-pharmacologically induced prolonged QTc interval
- History of additional risk factors for torsades de pointes
- Peripheral neuropathy Grade ≥ 2
- Known active infections
- Active gastrointestinal disease or other malabsorption syndromes
- Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase
inhibitor-induced pneumonitis
- Other protocol specified criteria
Studien-Rationale
Primary outcome:1. Objective Response Rate (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RECIST v1.1
Secondary outcome:
1. Duration of Response (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RECIST v1.1
2. Time to Response (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RECIST v1.1
3. Clinical Benefit Rate (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RECIST v1.1
4. Intracranial Tumor Response (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable
5. CNS Progression-free Survival (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable
6. Progression-free Survival (Time Frame - Approximately 30 months):
Assessed by Kaplan-Meier method
7. Overall Survival (Time Frame - Approximately 36 months):
Assessed by Kaplan-Meier method
8. Population PK (Time Frame - Approximately 24 months):
Assessed by Kaplan-Meier method
9. Adverse Events (Time Frame - Approximately 36 months):
Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, graded by the NCI CTCAE
10. Quality of Life (Time Frame - Approximately 24 months):
Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the Euro-QoL Group EQ-5D. NSCLC and mCRC patients will complete the lung cancer and colorectal cancer specific modules, QLQ-LC13 and QLQ-CR29, respectively
11. Bone Growth and Bone Mineral Density (Time Frame - Approximately 30 months):
Assessed with DHA scans
12. Bone Biomarkers (Time Frame - Approximately 30 months):
Measured by blood
Studien-Arme
- Experimental: NTRK1/2/3-rearranged NSCLC
Oral entrectinib (RXDX-101) - Experimental: ROS1-rearranged NSCLC
Oral entrectinib (RXDX-101) - Experimental: ALK- or ROS1-rearranged NSCLC
with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.) Oral entrectinib (RXDX-101) - Experimental: NTRK/1/2/3-rearranged mCRC
Oral entrectinib (RXDX-101) - Experimental: ROS1-rearranged mCRC
Oral entrectinib (RXDX-101) - Experimental: ALK-rearranged mCRC
Oral entrectinib (RXDX-101) - Experimental: NTRK1/2/3-rearranged other solid tumor
Oral entrectinib (RXDX-101) - Experimental: ROS1-rearranged other solid tumor
Oral entrectinib (RXDX-101) - Experimental: ALK-rearranged other solid tumor
Oral entrectinib (RXDX-101)
Geprüfte Regime
- Entrectinib (RXDX-101):
TrkA/B/C, ROS1, and ALK inhibitor
Quelle: ClinicalTrials.gov